Summary: Learn more about the shift from in-clinic to remote pulse oximetry and understand the real-world impact of DiMe’s Playbook in an informative digest from Koneksa.
The COVID-19 pandemic has caused many digital technologies to gain traction in public health, clinical care, and clinical research, increasing available options for those who receive care and those who deliver it. Digital endpoints can provide continuous data streams, measure real-world activity, offer at-home monitoring convenience, and unlock countless benefits for patients and researchers.
Pulse oximeter devices, which were more accessible than monitoring blood oxygen with PCR-based tests, captured the attention of the public at the beginning of the pandemic as an easy way to assess blood oxygen levels from the comfort of home. Purchased over the counter, the non-invasive device enabled personal health monitoring, as well as remote triaging for doctors and researchers.
At-home pulse oximetry, like other types of remote monitoring, does prompt questions about the reliability of OTC devices, their effect on unsupervised patient compliance, and the quality of remotely collected data. But advocates of moving more in-clinic technologies and processes to remote settings are pulling their experience together to document best practices for new initiatives.
The Digital Medicine Society (DiMe), a multidisciplinary group of industry leaders, regulators, and patient advocates, has created a valuable manual for developing and deploying digital clinical measures and remote monitoring. Containing 400 pages of strategies and tips, The Playbook is an action-oriented guide that strengthens the growing analytical and clinical evidence base for digital medicine today.
Moving a well-established digital measure from the clinic to the home changes the context of its use, but with information from The Playbook, researchers can effectively implement pulse oximeters as a remote diagnostic measure for respiratory infections, lung cancer, and several other conditions.
Koneksa’s expertise in digital biomarkers has informed a remote monitoring decision tree that may also help industry professionals determine whether similar assessments can manage the in-clinic to remote migration and remain valid, safe, usable measurements.
And DiMe’s EVIDENCE Checklist for digital product evaluations adds even more to the toolbox to encourage high-quality research and peer-reviewed literature in the digital medicine space.
As new studies continue to utilize digital clinical measures, industry-wide collaboration will help solidify best practices and promote the adoption of innovative endpoints that support remote monitoring opportunities.
You can learn more about the shift from in-clinic to remote pulse oximetry, and understand the real-world impact of DiMe’s Playbook, in an informative digest from Koneksa.